Beta blockers may reduce mortality in cluster of young patients with AF and HF: Lancet

The results of the study are as follows:

• 15 659 patients with heart failure and LVEF of less than 50% were included, with median age 65 years and LVEF 27%, 3708 (24%) patients were women. In sinus rhythm, most clusters demonstrated a consistent overall mortality benefit from β blockers.
• One cluster in sinus rhythm of older patients with less severe symptoms showed no significant efficacy.
• In atrial fibrillation, four of five clusters were consistent with the overall neutral effect of β blockers versus placebo.
• One cluster of younger atrial fibrillation patients at lower mortality risk but similar LVEF to average had a statistically significant reduction in mortality with β blockers.
• The robustness and consistency of clustering was confirmed for all models and cluster membership was externally validated across the nine independent trials.

Thus, the researchers concluded that an artificial intelligence-based clustering approach was able to distinguish the prognostic response from β blockers in patients with heart failure and reduced LVEF. This included patients in sinus rhythm with suboptimal efficacy, as well as a cluster of patients with atrial fibrillation where β blockers did reduce mortality.

Reference:

Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine-learning cluster analysis by Karwath A et. al published in The Lancet.

DOI: https://doi.org/10.1016/S0140-6736(21)01638-X